Orive-Mauleón, D. (Daniel)

Filtering

2022 - 20242

Settings

Author search.filters.isAuthorOfPublication.95d7dce1-81fe-4e00-8b2b-2f9efe16679a

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Protein biomarkers in lung cancer screening: technical considerations and feasibility assessment
    (Elsevier, 2024) Seijo, L. (Luis); Calle-Arroyo, C. (Carlos) de la; Pineda-Lucena, A. (Antonio); Detterbeck, F. (Frank); Bernasconi-Bisio, F. (Franco); Johansson, M. (Mattias); Montuenga-Badia, L.M. (Luis M.); Orive-Mauleón, D. (Daniel); Hung, J.R. (Rayjean); Valencia, K. (Karmele); Echepare, M. (Mirari); Robbins, H.A. (Hilary); Fernandez-Sanmamed, M. (Miguel)
    Lung cancer remains the leading cause of cancer-related deaths worldwide, mainly due to late diagnosis and the presence of metastases. Several countries around the world have adopted nation-wide LDCT-based lung cancer screening that will benefit patients, shifting the stage at diagnosis to earlier stages with more therapeutic options. Biomarkers can help to optimize the screening process, as well as refine the TNM stratification of lung cancer patients, providing information regarding prognostics and recommending management strategies. Moreover, novel adjuvant strategies will clearly benefit from previous knowledge of the potential aggressiveness and biological traits of a given early-stage surgically resected tumor. This review focuses on proteins as promising biomarkers in the context of lung cancer screening. Despite great efforts, there are still no successful examples of biomarkers in lung cancer that have reached the clinics to be used in early detection and early management. Thus, the field of biomarkers in early lung cancer remains an evident unmet need. A more specific objective of this review is to present an up-to-date technical assessment of the potential use of protein biomarkers in early lung cancer detection and management. We provide an overview regarding the benefits, challenges, pitfalls and constraints in the development process of protein-based biomarkers. Additionally, we examine how a number of emerging protein analytical technologies may contribute to the optimization of novel robust biomarkers for screening and effective management of lung cancer.
  • Thumbnail Image
    Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small- cell lung cancer
    (BMJ, 2022) Martínez-Morilla, S. (Sandra); Zugazagoitia, J. (Jon); Moutafi, M.K. (Myrto K.); Molero, M. (Magdalena); Rimm, D.L. (David L.); Adradas, V. (Vera); Castro-Labrador, L. (Laura); Montuenga-Badia, L.M. (Luis M.); Vathiotis, I.A. (Ioannis A.); Orive-Mauleón, D. (Daniel); Gavrielatou, N. (Niki); Herbst, R.S. (Roy S.); Valencia, K. (Karmele); Paz-Ares, L. (Luis); Ruiz-de-Garibay, G. (Gorka); Baena, J. (Javier); Calvo-González, A. (Alfonso); Schalper, K.A. (Kurt A.); Ponce-Aix, S. (S.)
    Most patients with advanced non-small-cell lung cancer (NSCLC) fail to derive significant benefit from programmed cell death protein-1 (PD-1) axis blockade, and new biomarkers of response are needed. In this study, we aimed to discover and validate spatially resolved protein markers associated with sensitivity to PD-1 axis inhibition in NSCLC.